Cary Street Partners Financial LLC Increases Stake in Bristol Myers Squibb Company $BMY

Cary Street Partners Financial LLC grew its stake in Bristol Myers Squibb Company (NYSE:BMY) by 11.6% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 106,445 shares of the biopharmaceutical company’s stock after purchasing an additional 11,086 shares during the period. Cary Street Partners Financial LLC’s holdings in Bristol Myers Squibb were worth $4,801,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the company. Darwin Wealth Management LLC acquired a new stake in Bristol Myers Squibb during the second quarter valued at $25,000. Harbor Capital Advisors Inc. boosted its stake in shares of Bristol Myers Squibb by 107.2% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 605 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 313 shares in the last quarter. Total Investment Management Inc. acquired a new stake in shares of Bristol Myers Squibb during the 2nd quarter valued at about $38,000. Twin Peaks Wealth Advisors LLC purchased a new position in shares of Bristol Myers Squibb in the 2nd quarter valued at about $40,000. Finally, Mark Sheptoff Financial Planning LLC raised its holdings in Bristol Myers Squibb by 233.3% in the 2nd quarter. Mark Sheptoff Financial Planning LLC now owns 1,000 shares of the biopharmaceutical company’s stock worth $46,000 after purchasing an additional 700 shares during the period. 76.41% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

BMY has been the topic of several research analyst reports. Morgan Stanley reissued an “underweight” rating and issued a $40.00 price objective on shares of Bristol Myers Squibb in a report on Friday, February 6th. BMO Capital Markets restated a “market perform” rating on shares of Bristol Myers Squibb in a report on Monday, November 17th. Wells Fargo & Company reissued an “outperform” rating and issued a $60.00 target price (up from $55.00) on shares of Bristol Myers Squibb in a research note on Friday, February 6th. Citigroup boosted their price target on shares of Bristol Myers Squibb from $60.00 to $64.00 and gave the company a “neutral” rating in a research report on Friday, February 6th. Finally, Guggenheim reiterated a “buy” rating and issued a $72.00 price objective (up from $62.00) on shares of Bristol Myers Squibb in a report on Friday, February 6th. Nine analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Bristol Myers Squibb presently has a consensus rating of “Hold” and a consensus price target of $60.71.

Bristol Myers Squibb Price Performance

Shares of NYSE:BMY opened at $61.32 on Thursday. Bristol Myers Squibb Company has a 12 month low of $42.52 and a 12 month high of $63.33. The firm has a market capitalization of $124.88 billion, a P/E ratio of 17.78, a P/E/G ratio of 0.18 and a beta of 0.29. The company has a debt-to-equity ratio of 2.32, a current ratio of 1.26 and a quick ratio of 1.14. The company’s fifty day moving average price is $56.66 and its 200 day moving average price is $50.33.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.65 by ($0.39). Bristol Myers Squibb had a return on equity of 69.65% and a net margin of 14.64%.The firm had revenue of $12.50 billion for the quarter, compared to analysts’ expectations of $12.24 billion. During the same period in the previous year, the business posted $1.67 EPS. The business’s revenue for the quarter was up 1.3% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, sell-side analysts predict that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, February 2nd. Shareholders of record on Friday, January 2nd were paid a $0.63 dividend. This is an increase from Bristol Myers Squibb’s previous quarterly dividend of $0.62. This represents a $2.52 dividend on an annualized basis and a yield of 4.1%. The ex-dividend date was Friday, January 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is presently 73.04%.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.